SCHEMBL4929490

SCHEMBL4929490

CSc1scc2c1C(=O)NC(C)(C)C2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.41
HPGD P15428 3/20 0.38
HSD17B10 Q99714 2/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
GFER P55789 1/20 0.36
DUSP10 Q9Y6W6 1/20 0.34
LRRK2 Q5S007 3/20 0.33
TSHR P16473 1/20 0.33
ALOX15 P16050 1/20 0.32
GABRG2 P18507 4/20 0.32
GABRB3 P28472 4/20 0.32
GABRA5 P31644 4/20 0.32
GABRA1 P14867 3/20 0.32
GABRA3 P34903 3/20 0.32
GABRA2 P47869 3/20 0.32
CDC7 O00311 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2C19 P33261 1/20 0.31
CDK5 Q00535 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4923925 0.65 HTT (0.54) HTTHPGDHSD17B10KDM4EALDH1A1
SCHEMBL22057654 0.65 HSD17B10 (0.38) HTTHSD17B10ALDH1A1TSHRALOX15
SCHEMBL7364727 0.64 KDM4E (0.43) KDM4EALDH1A1DUSP10LRRK2
SCHEMBL20702295 0.59
SCHEMBL4842012 0.59 NPSR1 (0.62) HTTHPGDHSD17B10KDM4EALDH1A1
SCHEMBL6434186 0.58 HTT (0.46) HTTHPGDHSD17B10KDM4EALDH1A1
SCHEMBL6436014 0.57 HTT (0.45) HTTHPGDHSD17B10KDM4EALDH1A1
SCHEMBL22803137 0.57 DUSP10 (0.37) KDM4EALDH1A1DUSP10
SCHEMBL7476279 0.57 HPGD (0.41) HTTHPGDHSD17B10KDM4EALDH1A1
SCHEMBL12204526 0.56 DUSP10 (0.41) KDM4EALDH1A1DUSP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275066-A1 Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists NOVO NORDISK A/S (DK) 2008-11-06 US disclosed
US-20080275066-A1 Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists NOVO NORDISK A/S (DK) 2008-11-06 US disclosed
US-20080275066-A1 Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists NOVO NORDISK A/S (DK) 2008-11-06 US disclosed
EP-1765814-A1 CONDENSED THIOPHENE DERIVATIVES AND THEIR USE AS CYCLIC GLP-1 AGONISTS NOVO NORDISK A/S (DK) 2007-03-28 EP disclosed
WO-2006003096-A1 CONDENSED THIOPHENE DERIVATIVES AND THEIR USE AS CYCLIC GLP-1 AGONISTS NOVO NORDISK A/S (DK) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275066-A1 Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists GLP1R, GIPR, GCGR HTT 1557/4885HPGD 1769/4885HSD17B10 1766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.